ABSTRACT To examine the effect of corticosteroids on bronchial hyperresponsiveness, a randomised, double dummy, single blind crossover study was performed in 18 subjects with chronic asthma, comparing the effect of three weeks' treatment with inhaled beclomethasone dipropionate, 1200 ,ug daily, and oral prednisone 12 5 mg daily. The 12 week study began with a three week run in period of baseline treatment, which was continued unchanged throughout the study, and the two treatment periods were separated by a three week washout period. Patients kept daily Airflometer readings and attended the laboratory every three weeks for spirometry and a histamine inhalation test for determining the provocative dose ofhistamine causing a 20% fall in FEV1 (PD20). The mean FEV, at the start was 1 9 litres (56% predicted). There was no significant change in PD20 with prednisone treatment, the mean PD20 being 0 56 and 0 59 umol before and after treatment. There was, however, a significant improvement in PD20 with beclomethasone dipropionate treatment, the geometric mean PD20 being 0 38 and 1 01 umol before and after treatment (p < 0-001). There was a small but significant improvement in mean FEVY after beclomethasone dipropionate treatment-from 1-9 to 2 2 litres-but no change after prednisone. Both medications produced significant and similar improvements in morning and evening Airflometer readings, post-bronchodilator improvement, and diurnal variation. Thus at doses that had similar beneficial effects on lung function beclomethasone dipropionate caused a significant improvement in bronchial hyperresponsiveness whereas prednisone caused no change. The superior topical anti-inflammatory effect of beclomethasone dipropionate may account for the different effects on bronchial hyperresponsiveness.
Although the mechanisms underlying bronchial hyperresponsiveness in asthma are still poorly understood, there is increasing evidence that airway inflammation has a major role in its development and maintenance.' Corticosteroids have been shown to diminish bronchial hyperresponsiveness caused by methacholine when this is given orally in high doses45 and to reverse allergen induced increases in responsiveness.' Several studies, however, have failed to show any effect of oral corticosteroids on bronchial hyperresponsiveness.78 More recent studies suggest that inhaled corticosteroids may be more effective in reducing it, although the magnitude of response in different studies has been variable. 9'" As no prospective study of the effect of equipotent doses of oral and inhaled corticosteroids has been performed, the present study was designed to compare the relative efficacy of an inhaled corticosteroid (beclomethasone dipropionate) with 
Results
Geometric mean PD20 values at the start of the oral and inhaled treatment periods were not significantly different (table 2) . There was a significant increase in geometric mean PD20 during the beclomethasone dipropionate treatment period-from 0-38 Pmol at the beginning to 101 pmol after three weeks (p < 0 001). The mean PD20 for the subjects taking prednisone did not change, being 0-56 pmol initially and 0 59 pmol after three weeks (table 2, fig 1) . No treatment effect was identified when PD20 at completion of the baseline period was compared with values at the end of the washout period (geometric mean PD20 being 0-43 and 0-48 pmol respectively).
Mean FEV, values showed a small but significant improvement during the beclomethasone treatment period from 19 to 2 2 litres. There was no change in FEV, during the prednisone treatment period, the mean FEV, at the beginning and end being 2 0 litres (table 3, fig 2) . Morning Airflometer readings before and after bronchodilator were, however, significantly higher during both beclomethasone and prednisone treatment than the baseline values. The mean morning Airflometer readings were 60 1 with beclomethasone and 60 8 with prednisone, compared with 44-3 during the baseline period (p < 0 001). Post-bronchodilator morning Airflometer readings rose to 772 with beclomethasone and 78-6 with prednisone (p < 0-01). The mean evening Airflometer readings were also higher with prednisone (715) and beclomethasone 380 Jenkins, Woolcock The differences between oral and aerosol corticosteroids could reflect differences in their site of action, changes in bronchial hyperresponsiveness reflecting changes mainly in large airways. This is unlikely for several reasons. Oral corticosteroids are unlikely to affect only small airways, and indeed both oral and aerosol corticosteroids produced significant improvements in Airflometer readings, suggesting that the effect of both drugs was widespread throughout the airways. In addition, it has been shown that there are no differences in PD20 when histamine is deposited
